#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15228	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2533	741.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1890	1890	T	959	T,G,C	955,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15228	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2533	741.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1624	1624	C	985	C,G,A	983,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4197	798.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	2056	2056	A	1166	A,C	1164,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4197	798.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2690	2690	C	1000	C,T,A	995,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4197	798.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2764	2764	A	953	A	953	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26846	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4197	798.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3316	3316	C	944	C,T	942,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	27	2062	folP	852	852	99.77	folP.l15.c17.ctg.1	1994	129.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5534	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3770	183.1	1	SNP	p	S91F	0	.	.	271	273	TCC	772	774	TCC	218;217;217	T;C;C	218;217;217	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5534	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3770	183.1	1	SNP	p	D95G	0	.	.	283	285	GAC	784	786	GAC	222;226;225	G;A,C;C	222;225,1;225	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5534	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3770	183.1	1	SNP	p	D95N	0	.	.	283	285	GAC	784	786	GAC	222;226;225	G;A,C;C	222;225,1;225	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1856	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1977	117.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	811	813	ACC	213;211;213	A;C;C	213;211;213	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1856	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1977	117.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	1009	1011	CAC	232;235;238	C,A;A,T;C	231,1;234,1;238	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1856	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1977	117.3	0	.	p	.	0	E117K	NONSYN	349	351	GAA	1045	1047	AAA	236;234;233	A;A;A	236;234;233	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1856	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1977	117.3	1	SNP	p	G45D	0	.	.	133	135	GGC	829	831	GGC	223;224;225	G;G;C	223;224;225	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1182	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1255	116.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1612	1614	ATC	251;251;251	A,C;T,A;C	250,1;250,1;251	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1765	1767	GCA	262;264;266	G;C,A;A	262;263,1;266	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2248	2250	ATT	270;271;270	A;T;T,G,C	270;271;268,1,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	1	SNP	p	D86N	0	.	.	256	258	GAC	718	720	GAC	248;247;244	G;A,G,C;C	248;245,1,1;244	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	1	SNP	p	S87R	0	.	.	259	261	AGT	721	723	AGT	244;243;244	A;G;T	244;243;244	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	1	SNP	p	S87W	0	.	.	259	261	AGT	721	723	AGT	244;243;244	A;G;T	244;243;244	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	1	SNP	p	S87I	0	.	.	259	261	AGT	721	723	AGT	244;243;244	A;G;T	244;243;244	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5526	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3354	205.4	1	SNP	p	S88P	0	.	.	262	264	TCC	724	726	TCC	243;245;248	T;C;C	243;245;248	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4152	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3058	169.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1782	1784	GGC	211;211;209	G,T;G;C	210,1;211;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1477	1479	GCA	186;187;189	G;C;A	186;187;189	penA.19.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1480	1482	ATC	189;190;190	A,G;T;C	188,1;190;190	penA.19.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1492	1494	GTG	191;195;195	G,T;T;G	190,1;195;195	penA.19.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1492	1494	GTG	191;195;195	G,T;T;G	190,1;195;195	penA.19.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1996	1998	ACC	211;212;213	A;C;C,A	211;212;212,1	penA.19.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2050	2052	GCG	206;207;211	G;C,G;G,T	206;206,1;209,2	penA.19.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2050	2052	GCG	206;207;211	G;C,G;G,T	206;206,1;209,2	penA.19.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2173	2175	GGT	242;241;238	G;G;T	242;241;238	penA.19.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2182	2184	GGC	230;230;228	G;G;C	230;230;228	penA.19.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.19.001	penA.19.001	1	1	27	3894	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2805	173.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2200	2202	CCG	224;224;224	C;C;G	224;224;224	penA.19.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5956	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3514	211.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2620	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2129	152.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	748	748	C	210	C	210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	0	.	p	.	0	E38G	NONSYN	112	114	GAA	589	591	GGA	255;254;252	G;G,A;A,G	255;253,1;251,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	0	.	p	.	0	G46S	NONSYN	136	138	GGC	613	615	AGC	257;257;258	A,T;G,A;C,A,G	256,1;255,2;256,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	0	.	p	.	0	V98I	NONSYN	292	294	GTC	769	771	ATC	220;214;212	A;T;C	220;214;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	0	.	p	.	0	R143E	NONSYN	427	429	AGA	904	906	GAA	266;266;266	G,A;A;A	264,1;266;266	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1108	1108	T	256	T	256	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	1	SNP	p	A121D	0	.	.	361	363	GCC	838	840	GCC	229;227;229	G;C,A;C	229;225,2;229	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2912	porB1b	1035	1035	97.71	porB1b.l15.c30.ctg.1	1666	210.6	1	SNP	p	A121N	0	.	.	361	363	GCC	838	840	GCC	229;227;229	G;C,A;C	229;225,2;229	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10190	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5417	234.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2261	2263	CAT	253;253;252	C;A;T	253;253;252	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1518	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1568	120.9	1	SNP	p	V57M	0	.	.	169	171	GTG	707	709	GTG	268;267;266	G,A;T;G	267,1;267;266	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
